84
In contrast, a R263K substitution was selected in tissue culture with DTG and this 85 substitution has been reported in several treatment-experienced, INSTI-naïve individuals 86 who were not fully suppressed when receiving DTG-based therapy (7). We showed that 87 R263K alone or in combination with other secondary mutations confers low-level 88 resistance to DTG and that viruses containing R263K possess significantly reduced viral 89 replication capacity (8-10).
90
It is also notable that R263K has been shown to emerge secondary to the T66I 
119
After 48 h, culture fluids were harvested and passed through a 0.45-µm filter.
120
Quantification of viruses was performed using p24 and RT assays as described previously 
Susceptibility to antiretroviral compounds

139
Susceptibilities of virus to ARVs were measured by addition of serially diluted DTG,
140
RAL, or EVG to TZM-bl cells prior to infection using the viruses described above.
141
Luciferase levels were measured after 48 h of incubation, similar to the protocol for the 142 infectivity assay described above, and IC 50 values were determined.
143
Generation of plasmids for integrase protein expression and
Expression plasmids pET-15b coding for soluble integrases that were either wild-type
146
(WT) or containing the R263K or E138K/R263K substitutions were generated using site-147 directed mutagenesis as previously described (10). The T66I, T66I/R263K, and
148
T66I/E138K/R263K combinations of mutations were produced using the primers experienced, INSTI-naïve individuals who experienced DTG-based treatment failure (7).
274
We have shown previously that the R263K substitution is also associated with decreases (Tables 2 and 3) .
286
The positive effect of E138K on strand-transfer activity seems to be due to an 287 improvement in DNA binding activity, as shown by decreases in 1/2Max DNA values when 288 this substitution was present (Table 2 ). In contrast, E138K had little effect on maximal the T66I/R263K combination of mutations (Figures 1 and 2 ). The addition of the E138K 292 substitution to the T66I/R263K combination also increased levels of resistance against
293
RAL and EVG by 1.5-and 7.5-fold, respectively (Table 4) .
294
Importantly, the addition of R263K to T66I did not confer resistance against DTG,
295
although it may have moderated the increase in susceptibility to this drug that was 296 associated with T66I alone (Table 4) . Furthermore, the T66I/R263K combination of 
303
In the current study, we also tested the ability of E138K, a secondary substitution that has 304 been observed together with R263K in tissue culture, to act together with the 305 T66I/R263K combination of mutations to modulate strand-transfer activity and 306 replicative capacity (Table 2 and Figures 1 and 2 ). However, viruses that contain the 307 T66I/E138K/R263K combination of substitutions remained highly susceptible to DTG 308 (Table 4) .
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